{"disease":{"id":"hepatocellular-carcinoma-non-resectable","name":"hepatocellular carcinoma non resectable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03283956","title":"Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05608200","title":"Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":427,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06904183","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05057104","title":"Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT07368023","title":"A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Ningbo Medical Center Lihuili Hospital","has_results":false},{"nct_id":"NCT05717738","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05713994","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Ze-yang Ding, MD","has_results":false},{"nct_id":"NCT05985798","title":"Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":258,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06916546","title":"SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC","phase":"","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT02989922","title":"A Study to Evaluate SHR-1210 in Subjects With Advanced HCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":true},{"nct_id":"NCT04967482","title":"DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":216,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06265883","title":"Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT","phase":"","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05543304","title":"Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT05608213","title":"Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06492395","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":178,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT04967495","title":"TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":171,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05390112","title":"Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization","phase":"","overall_status":"UNKNOWN","enrollment_count":167,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04718909","title":"Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":166,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03864211","title":"Thermal Ablation Followed by Immunotherapy for HCC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":145,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04997850","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Xinrui Zhu，MD","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06397235","title":"DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT04224636","title":"Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false},{"nct_id":"NCT03277716","title":"Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fan Weijun","has_results":false},{"nct_id":"NCT03652467","title":"The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Jinan Military General Hospital","has_results":false},{"nct_id":"NCT05638438","title":"Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06712017","title":"Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"GrandPharma (China) Co., Ltd.","has_results":false},{"nct_id":"NCT04966195","title":"Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07122089","title":"Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Center Eugene Marquis","has_results":false},{"nct_id":"NCT04965454","title":"Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Queen's Medical Center","has_results":false},{"nct_id":"NCT06904196","title":"Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT07110233","title":"Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03533920","title":"Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Jeil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04273100","title":"PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04522544","title":"Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT05911633","title":"BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Terumo Europe N.V.","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06408753","title":"Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06133062","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06487663","title":"TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06187961","title":"Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04592029","title":"TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05530785","title":"Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Yongchang Zhang","has_results":false},{"nct_id":"NCT06707233","title":"Y-90 SIRT for Unresectable HCC Larger Than 7cm","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT01835223","title":"Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT06375486","title":"Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05114148","title":"Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT04599790","title":"TACE Combined With Lenvatinib and Sintilimab for Advanced HCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}